OG716 is a molecule derived from our lantibiotic discovery and characterization platform that has shown positive results in nonclinical testing including an animal model for Clostridium difficile infection in enteritis.
More on OG716 »AG013 represents a promising product from a truly innovative platform for the prevention of oral mucositis in cancer patients.
More on AG013 »